TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06390956: Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Sponsor: University of Utah · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 23 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$4,620,000

Rescue Site Savings

+$3,049,200

Unlock Full NCT06390956 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06390956 Rescue Dossier →